secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2021-08-26T23:59:59+00:00
Accession:  0001104659-21-109807
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

EyeGate VP Engineering Michael Manzo departs as of Aug 20, 2021
---------------------------------------------------------------

- Michael Manzo ceased serving as VP of Engineering effective August 20, 2021.
- No replacement has been announced; remaining executive team unchanged.
- Departure follows customary transition; no reason provided in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921109807/0001104659-21-109807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921109807/tm2117495d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-109807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer